A Phase 3 interventional study of ELX/TEZ/IVA and IVA in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 34 sites in 10 countries. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2024-05-08.
Sponsored by Vertex Pharmaceuticals Incorporated · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies testing elexacaftor in Cystic Fibrosis — 2 open to participants now, 5 under way, 2 of them phase 3. elexacaftor · Cystic Fibrosis.
Among the 23 studies testing elexacaftor in Cystic Fibrosis, this one is the 12th largest by enrollment, is one of 3 that started in 2021, is one of 19 in phase 3, and was the 12th registered.
1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.
Browse Cystic Fibrosis studies →2 of the 23 studies testing elexacaftor in Cystic Fibrosis are open now, in 2 countries. Recruiting first, the newest first:
Istituto Giannina Gaslini · Sites in Italy
Ages 6+
Arkansas Children's Hospital Research Institute · Sites in United States
Ages 3+
By country, each count listing its studies:
elexacaftor: first FDA approval 2019 (TRIKAFTA (COPACKAGED)), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.
This study: 6 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
First in 2017; this study’s year is marked. 3 started in 2021.
This study's enrollment of 120 is above the median of 36 across 1,053 interventional studies indexed under Cystic Fibrosis.
Median enrollment 120 across the 23 interventional studies. Of the 18 that completed or were terminated, 17 (94%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 23 have an industry lead sponsor. The 4 most frequent:
Vertex Pharmaceuticals Incorporated is the lead sponsor of 249 studies on the registry; 17 are open to participants now.
Of its 107 completed or terminated interventional studies of FDA-regulated products, 54 (50%) have results posted.
125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated: 3 open now, 8 under way, 5 of them phase 3. Of 112 finished, 80 (71%) have results posted.
Among the 125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated, this one is the 43rd largest by enrollment of the 116 interventional ones that give a count, is one of 6 that started in 2021, is one of 62 in phase 3, and was the 96th registered.
Vertex Pharmaceuticals Incorporated’s Cystic Fibrosis studies by the year they started, since 2007.
2 of the studies testing elexacaftor in Cystic Fibrosis that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05331183Phase 3Vertex Pharmaceuticals IncorporatedStudy to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del | 2027-04-06 |
| NCT06460506Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older | 2027-09-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 23 studies testing elexacaftor in Cystic Fibrosis, from their registry updates:
Among Vertex Pharmaceuticals Incorporated’s 125 in Cystic Fibrosis:
This tab as a report to print or save as PDF → With an account.
The study evaluates the long-term safety and efficacy of elexacaftor (ELX)/tezacaftor (TEZ)/ivacaftor (IVA) triple combination (TC) in participants with CF who are 6 years of age and older with F/MF genotypes.
Key Inclusion Criteria:
Key Exclusion Criteria:
Other protocol defined Inclusion/Exclusion criteria may apply
Participants 6 to less than \<12 year of age and weighing \<30 kilogram (kg) at Day 1 received ELX 100 milligram (mg)/TEZ 50 mg /IVA 75 mg as fixed dose combination (FDC) tablets in the morning and IVA as mono tablet in the evening and those weighing more than or equal to (≥) 30 kg at Day 1 received ELX 200 mg/TEZ 100 mg /IVA 150 mg as FDC tablets in the morning and IVA as mono tablet in the evening for 96 weeks. Doses were adjusted upward with subsequent changes in weight. Participants ≥12 years age at Day 1 received ELX 200 mg/TEZ 100 mg/IVA 150 mg as FDC tablets in the morning and IVA as mono tablet in the evening for 96 weeks.
Drug: ELX/TEZ/IVA · Drug: IVA
Drug pages: Elexacaftor · Tezacaftor · Ivacaftor
Fixed dose combination (FDC) tablets for oral administration.
Also known as: VX-445/VX-661/VX-770, elexacaftor/tezacaftor/ivacaftor
Tablet for oral administration.
Also known as: VX-770, ivacaftor
Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame: From Baseline up to Week 100
Absolute Change From Parent Study Baseline in Sweat Chloride (SwCl)
Sweat samples were collected using an approved collection device.
Time frame: From Parent Study Baseline to Week 96
Absolute Change From Parent Study Baseline in Lung Clearance Index 2.5 (LCI2.5)
The LCI2.5 index is the number of lung turnovers required to reduce the end tidal inert gas concentration to 1/40th of its starting values and is calculated by dividing the sum of exhaled tidal breaths (cumulative exhaled volume (CEV)) by simultaneously measured functional residual capacity (FRC). An LCI of 7.5 and below is normal; values greater than 7.5 are abnormal. LCI is able to detect abnormalities in lung function earlier than more traditional modalities such as spirometry.
Time frame: From Parent Study Baseline to Week 96
| Milestone | ELX/TEZ/IVA |
|---|---|
| Started | 120 |
| Placebo-elx/tez/iva | 61 |
| Elx/tez/iva-elx/tez/iva | 59 |
| Completed | 110 |
| Not completed | 10 |
| Withdrew: Adverse event | 1 |
| Withdrew: Withdrawal of consent (not due to ae) | 2 |
| Withdrew: Commercial drug is available for participant | 7 |
| Participants | ELX/TEZ/IVA |
|---|---|
| Participants with TEAEs | 118 |
| Participants with SAEs | 13 |
Sweat samples were collected using an approved collection device.
| millimole per liter (mmol/L) | ELX/TEZ/IVA |
|---|---|
| Placebo (Parent study)-ELX/TEZ/IVA (Current study) | -57.3 ± 2.2 |
| ELX/TEZ/IVA (Parent study)-ELX/TEZ/IVA (Current study) | -57.5 ± 2.3 |
The LCI2.5 index is the number of lung turnovers required to reduce the end tidal inert gas concentration to 1/40th of its starting values and is calculated by dividing the sum of exhaled tidal breaths (cumulative exhaled volume (CEV)) by simultaneously measured functional residual capacity (FRC). An LCI of 7.5 and below is normal; values greater than 7.5 are abnormal. LCI is able to detect abnormalities in lung function earlier than more traditional modalities such as spirometry.
| Index | ELX/TEZ/IVA |
|---|---|
| Placebo (Parent study)-ELX/TEZ/IVA (Current study) | -1.74 ± 0.18 |
| ELX/TEZ/IVA (Parent study)-ELX/TEZ/IVA (Current study) | -2.35 ± 0.19 |
Collected over Day 1 up to Week 100. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ELX/TEZ/IVA | 0/120 (0%) | 13/120 (10.8%) | 118/120 (98.3%) |
| Event | ELX/TEZ/IVA |
|---|---|
| Infective pulmonary exacerbation of cystic fibrosisInfections and infestations | 2/120 |
| ConstipationGastrointestinal disorders | 1/120 |
| EnteritisGastrointestinal disorders | 1/120 |
| Ileus paralyticGastrointestinal disorders | 1/120 |
| Intestinal obstructionGastrointestinal disorders | 1/120 |
| SteatorrhoeaGastrointestinal disorders | 1/120 |
| General physical health deteriorationGeneral disorders | 1/120 |
| Bacterial disease carrierInfections and infestations | 1/120 |
| Pneumonia pseudomonalInfections and infestations | 1/120 |
| Pneumonia staphylococcalInfections and infestations | 1/120 |
| Event | ELX/TEZ/IVA |
|---|---|
| COVID-19Infections and infestations | 70/120 |
| CoughRespiratory, thoracic and mediastinal disorders | 62/120 |
| NasopharyngitisInfections and infestations | 54/120 |
| PyrexiaGeneral disorders | 48/120 |
| HeadacheNervous system disorders | 45/120 |
| Upper respiratory tract infectionInfections and infestations | 37/120 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 32/120 |
| RhinitisInfections and infestations | 29/120 |
| Abdominal painGastrointestinal disorders | 27/120 |
| VomitingGastrointestinal disorders | 24/120 |
Baseline data for the long-term safety analysis is based on the parent study baseline, which is defined as the most recent non-missing measurement collected before the first dose of study drug in the treatment period of parent study.
| Age, Continuous(years) | ELX/TEZ/IVA |
|---|---|
| Mean | 9.1 ± 1.7 |
| Sex: Female, Male(Participants) | ELX/TEZ/IVA |
|---|---|
| Female | 69 |
| Male | 51 |
| Race/Ethnicity, Customized(Participants) | ELX/TEZ/IVA |
|---|---|
| Hispanic or Latino | 1 |
| Not Hispanic or Latino | 90 |
| Not collected per local regulations | 29 |
| Race/Ethnicity, Customized(Participants) | ELX/TEZ/IVA |
|---|---|
| White | 87 |
| Black or African American | 1 |
| Asian | 1 |
| American Indian or Alaska Native | 1 |
| Other | 1 |
| Not collected per local Regulations | 28 |
| Multiracial | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/independent-research/clinical-trial-data-sharing
Ran from Jan 2021 to primary completion in Mar 2023, 26 months.
Results were first posted in May 2024, 1 year 1 month after primary completion.
Of 58 industry-sponsored phase 3 interventional studies under Cystic Fibrosis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 36. This study's 26 months is close to that.
Counting every sponsor, half of 67 studies reached it within 26 months; a quarter within 16 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Elexacaftor · Tezacaftor · Ivacaftor
Vertex Pharmaceuticals Incorporated →